The Relx-backed big data analyser is reportedly lining up a confidential IPO filing in the coming weeks having previously raised $1.9bn in equity funding.

Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.

AstraZeneca and Fresenius Medical Care will exit the kidney disease treatment developer in a $725m acquisition that could potentially rise to $2.1bn.

The mobile optimisation technology provider, whose backers include Verizon Ventures, is set to be bought by Volaris Group.

Siemens and Scania-backed Sennder has merged with fellow on-demand logistics provider Everoad to seize a larger chunk of the European marketplace.

Genscript Biotech's multiple myeloma-focused spinoff, which counts Eli Lilly and Johnson & Johnson among its investors, has completed an initial public offering in the US.

Capital One and Salesforce-backed cloud database provider Snowflake has confidentially filed for an initial public offering that could value it at up to $20bn.

RWS Holdings had bought language translation software developer Iconic Translation Machines, founded on DCU's research into translating patents.

Johnson & Johnson and Varian Medical Systems are in line for exits after cancer therapy developer Fusion filed for a $100m initial public offering.

The cancer diagnostics technology developer, formed five years ago when Qiagen acquired part of Enzymatics, has filed to float on the Nasdaq Global Market.